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RESUMO – A incidência do melanoma está a aumentar de uma forma global e essa tendência manter-se-á muito provavelmen-
te nas próximas duas décadas. Estes dados reforçam a necessidade de novos alvos terapêuticos, em alternativa à quimioterapia 
clássica para o tratamento do melanoma avançado. Com efeito, ao longo da última década, os novos conhecimentos relativos à 
biologia tumoral revolucionaram a terapêutica do melanoma, incluindo a imunoterapia com os inibidores dos “checkpoints” imu-
nológicos, cujos alvos terapêuticos são as proteínas CTLA-4 (cytotoxic T lymphocyte-associated protein 4) e PD-1 (programmed cell 
death protein 1). A inibição destes alvos permite a modulação da resposta imune do hospedeiro contra o desenvolvimento tumoral, 
com respostas objetivas sustentadas no controlo da doença. Face a estes resultados, a imunoterapia tornou-se o tratamento de 
referência nos doentes com melanoma avançado (estadio III irressecável ou estadio IV, com metástases à distância), sem mutação 
BRAF identificada. O ipilimumab (anti CTLA-4) foi o primeiro “checkpoint” imunológico inibitório a demonstrar aumento na so-
brevida global no tratamento do melanoma avançado. Mais tarde, o nivolumab e o pembrolizumab (ambos anti-PD-1) evidencia-
ram melhores resultados em termos de sobrevida global e tolerabilidade do que o ipilimumab. Estes resultados são expectáveis, 
na medida em que as vias de inibição dos “checkpoints” imunológicos são diferentes. Neste contexto, impõe-se a avaliação da 
eficácia da terapêutica combinada e a identificação de biomarcadores que possibilitem a previsão de resposta aos anti-CTLA-4 e 
anti-PD-1.  Após um trabalho prévio em que foram sumariamente revistos os mecanismos de desenvolvimento tumoral e de ação 
dos “checkpoints” imunológicos inibitórios, propomo-nos efetuar uma revisão sobre os inibidores dos “checkpoints” imunológicos, 
atualmente disponíveis na prática clínica para o tratamento do melanoma avançado. 
PALAVRAS-CHAVE – Anticorpos Monoclonais; Antígeno CTLA-4; Imunoterapia; Ipilimumab; Melanoma; Nivolumab; Pembroli-
zumab; Pontos de Controlo do Ciclo Celular; Receptor de Morte Celular Programada 1.
Immune Checkpoint Inhibitors in Melanoma: Review 
and Update  
ABSTRACT – The overall increasing incidence of melanoma will very probably be the trend over the next two decades. This data 
stresses the need for new therapeutic resources, other than classic chemotherapy. Nevertheless, the treatment of advanced melanoma 
has been changed in the last decade due to novel therapeutic strategies, including immunotherapy with immune checkpoint inhibi-
tors targeting cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1). Inhibition of these 
targets enhances immune host response against cancer and results in durable objective responses, establishing immunotherapy as 
standard treatment for BRAF wild-type melanoma patients in advanced stages (III – unresectable and IV – metastases at distant sites). 
Anti-CTLA-4, ipilimumab, was the first–in-class immune checkpoint inhibitor to show improvement in overall survival in advanced 
melanoma. Latter, anti-PD-1 agents, nivolumab and pembrolizumab, have improved tumour response and tolerability in comparison 
with ipilimumab. Differences in outcome are expected considering the distinct target of checkpoint inhibition pathways. In this setting, 
it is of utmost importance the assessment of efficacy by combined therapy and the identification of biomarkers capable of predicting 
response to anti-CTLA-4 and anti-PD-1. After a previous review on cancer biology and mechanisms of action of immune checkpoint 
inhibitors we will focus on the main data on the immune checkpoint inhibitors for melanoma currently available in daily practice.  
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1 - INTRODUCTION
Cutaneous melanoma represents a minority of all skin 
cancers; however, it is responsible for 80% of skin cancer 
deaths.1 Diagnosis at earlier stages is associated with a bet-
ter prognosis. The risk of metastasis correlates directly with 
primary tumour thickness, occurring in approximately 35% 
to 50% of patients with T4b primary melanoma (thickness 
> 4.0 mm, with ulceration).2 The incidence of melanoma is 
increasing, and this trend will very probably continue throu-
ghout the next two decades.3,4 This data stresses the need for 
new therapeutic resources other than conventional chemo-
therapy, which is largely ineffective in patients with unresec-
table or metastatic melanoma.5 In the last decade, due to 
identification of activating mutations in melanoma6 and the 
role of the immune system in cancer, multiple new therapeu-
tic strategies have become available and radically transfor-
med the care of melanoma patients, particularly those with 
advanced stage disease.7,8 Thirty-five to 50% of patients with 
cutaneous melanoma harbour a BRAF 600 mutation.9 The-
refore, treatment of these patients with molecular targeted 
therapy using BRAF inhibitors alone or in combination with 
MEK inhibitors is recommended, although the majority will 
develop secondary resistance.10,11
Immunotherapy using immune checkpoint inhibitors 
(ICI) against cytotoxic T lymphocyte antigen - 4 (CTLA-4) 
and programmed death - 1 (PD-1) are now recommended 
for BRAF wild-type melanoma patients in advance stages (III 
– unresectable and IV – metastases at distant site(s))2 (Fig. 
1). After review cancer biology and mechanisms of action of 
immune checkpoint inhibitors,8 we will focus on the use of 
immune checkpoint inhibitors for melanoma currently avai-
lable in daily practice.
2 - IMMUNE CHECKPOINT INHIBITORS: MONO-
THERAPY 
2.1 – CTLA-4 inhibitors 
2.1.1 – Ipilimumab 
a) Mechanism of action 
The identification of CTLA-4 as a key molecule in the 
downregulation of T-cell activation leads to the hypothesis 
that a CTLA-4 blockade could promote anti-tumour immuni-
ty mediated by effector CD4 and CD8 T cells.12 Encouraging 
anti-tumour effects in animal models led to the development 
of human monoclonal antibodies which block CTLA-4.
Ipilimumab, a fully human monoclonal immunoglobulin 
(Ig)G1 antibody against CTLA-4, was the first drug introduced 
as immunotherapy for melanoma. Interaction of the mono-
clonal antibody with CTLA-4 blocks inhibitory signals gene-
rated through this receptor and enhances T cell activation, 
leading to increased anti-tumour responses.8,13,14 (Fig. 1). 
b) Long-term efficacy and toxicity 
Ipilimumab was investigated in several phase I and 
phase II clinical trials, which reported durable and consistent 
responses in patients with stage III unresectable or stage IV 
metastatic melanoma.15-19 The first phase III clinical trial was 
a large prospective multicentre randomised study that inclu-
ded patients diagnosed with unresectable stage III or IV me-
lanoma who had failed previous treatments. Patients were 
randomly assigned in a 3:1:1 ratio to receive ipilimumab 
3 mg/kg body weight alone, in combination with gp100 
(vaccine derived from melanossomal glycoprotein 100) or 
gp100 alone. The results showed no difference between the 
2 ipilimumab groups, with a median overall survival (OS) 
of 10 months, better than 6.4 months observed in patients 
receiving gp100 alone.17 Moreover, responses in the ipili-
mumab groups were sustained and durable, and gp100 
vaccine was inactive. The most common adverse events re-
lated to the study drugs were immune-related events, which 
occurred in approximately 60% of the patients treated with 
ipilimumab and 32% of the patients treated with gp100. 
Grade 3 or 4 toxicities occurred in 10% to 15% of the pa-
tients in the ipilimumab groups and in 3.0% of those in the 
gp100-alone group. Seven of the 14 total deaths occurred 
due to autoimmune side effects. The gastrointestinal tract 
(diarrhoea/colitis) and the skin (injection site reactions and 
vitiligo) were the most affected organs. Endocrine immune-
-related adverse events (e.g., inflammation of the pituitary 
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Figure 1 - (Adapted from Pardoll DM. Nat Rev Cancer. 2012;12:252–
6414): Regulation of T-cell response: balancing activating and inhibitory 
signals. Inhibition receptors (CTLA-4 and PD-1) are well-established tar-
gets for immunotherapy.  BTLA, LAG-3, TIM-3 are ongoing emerging 
targets for immunotherapy.
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gland) were also reported. Corticosteroids were critical for 
the management of immune-related adverse events. 
The second phase III clinical trial was carried out in pre-
viously untreated patients.20 Patients were randomly assig-
ned in a 1:1 ratio to receive ipilimumab (10 mg/kg) plus 
dacarbazine (850 mg/m2 of body-surface area) or dacar-
bazine (850 mg/m2) plus placebo. In this trial, the OS was 
significantly longer in the group receiving ipilimumab plus 
dacarbazine than in the group receiving dacarbazine plus 
placebo (11.2 months vs 9.1 months) (hazard ratio – HR 
for death with ipilimumab-dacarbazine: 0.72; p < 0.001) 
and the 3-year OS was 20.8% vs 12.2%, respectively. The 
incidence of adverse effects, regardless of the cause, was 
higher in the ipilimumab plus dacarbazine group than in the 
dacarbazine group, and included elevation of serum levels 
of alanine aminotransferase (in 33.2% of patients vs 5.6%) 
and aspartate aminotransferase (29.1% vs 5.6%), diarrhoea 
(36.4% vs 24.7%), pruritus (29.6% vs 8.8%) and rash (24.7% 
vs 6.8%). Further, grade 3 or 4 adverse events occurred in 
56.3% of patients receiving ipilimumab plus dacarbazine 
and in 27.5% of patients receiving placebo plus dacarba-
zine. Overall, immune-related adverse events were consi-
derably higher in the group treated with ipilimumab plus 
dacarbazine (77.7% vs 38.2%), with elevated liver function 
values, including grade 3 or 4, as the most common immu-
ne-related adverse event.
Another phase III multicentric clinical trial ascertained 
two different ipilimumab doses.21 Patients with unresectable 
stage III or IV melanoma, without previous therapy (BRAF 
inhibitors, CTLA-4 or PD-1/PDL-1 antagonists), were ran-
domly assigned (1:1) to ipilimumab 10 mg/kg vs 3 mg/
kg. The median OS was 15.7 months in the ipilimumab 10 
mg/kg group and 11.5 months in the 3 mg/kg group (HR 
0·84, 95% p = 0·04; 1-year OS was 54·3% in the 10 mg/
kg group vs 47.6% in the 3 mg/kg group; 2-year OS was 
38.5% vs 31.0% and 3-year OS was 31.2% vs 23.2%. The 
median progression-free survival (PFS) was 2.8 months in 
the 10 mg/kg group and 2.8 months in the 3 mg/kg group 
(Table 1). Globally, the incidence of adverse effects was hi-
gher in the 10 mg/kg group (79%) than in the 3 mg/kg 
group (63%). The most common grade 3 to 4 treatment-
-related adverse events were diarrhoea (10% in the 10 mg/
kg group vs 6% in the 3 mg/kg group), colitis (5% vs 2%), 
increased alanine aminotransferase (3% vs 1%), and hypo-
physitis (3% vs 2%). Overall, immune-related adverse events 
occurred in 74% of patients in the 10 mg/kg group com-
pared to 54% of patients in the 3 mg/kg group, most com-
monly diarrhoea, rash and pruritus. This trial demonstrated 
a significant improvement in OS with ipilimumab 10 mg/
kg, however, these higher doses were associated with more 
adverse effects, including auto-immunity.
c) Dosage 
Ipilimumab is currently approved for patients with unre-
sectable or metastatic melanoma at a recommended dose 
of 3 mg/kg administered intravenously over 90 minutes 
every 3 weeks for a total of 4 doses.22
2.2 – PD-1 inhibitors  
2.2.1 – Nivolumab
a) Mechanism of action: 
Nivolumab, a fully human monoclonal IgG4 antibody, 
binds to PD-1 receptors on T cells and blocks the binding of 
its ligands, PD-L1 and PD-L2, thereby releasing PD-1-me-
diated inhibition of the immune response8,14,22 (Fig. 1). In 
vitro, nivolumab exhibited high affinity and selective binding 
to PD-1 receptors, with no binding to other immunoglobulin 
super-family proteins, including CTLA-4 and CD28.23
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Table 1 - Average outcomes, progression free survival (PFS) and overall survival (OS), of immune checkpoint 
inhibitors, based on selected trials (Adapted from103)
Immunotherapy PFS at 6 months (%) OS at 12 months (%) OS at 24 months (%)
FIRST LINE
Anti-CTLA-4 (Ipilimumab) 39.3 50.4 28.6
Anti-PD-1 (Nivolumab or Pembrolizumab) 51.1 72.2 59.3
Combined therapy (Anti – CTLA-4 + Anti-PD-1) 63.8 73.1 62.9
SECOND LINE
Anti-CTLA-4 (Ipilimumab) 21.8 48.6 29.1
Anti-PD-1 (Nivolumab or Pembrolizumab) 40.2 62.1 45.3
Combined therapy (Anti – CTLA-4 + Anti-PD-1) 73.2 86.9 n.a.
Legend: n.a. not available 
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b) Long-term efficacy and toxicity 
A pilot study (phase I) with anti PD-1 immune checkpoint 
on solid tumours refractory to previous treatments demons-
trated evidence of anti-tumour activity with a good safety 
profile.24 Later, a larger phase I study corroborated the pre-
vious findings, showing a durable objective response with 
few adverse effects.25 Data from phase I (II) trials encoura-
ged further phase III studies, which supported the approval 
of nivolumab for unresectable/metastatic melanoma.26,27 
The Check-Mate-03726 was a multicentric, open label 
phase III, clinical trial that investigated nivolumab versus 
the investigator's choice of chemotherapy (ICC) in patients 
with unresectable stage III C or IV metastatic melanoma 
that had progressed after ipilimumab, or ipilimumab and 
a BRAF inhibitor (for patients with melanoma harbouring 
a BRAFV600E mutation). Patients were randomly assigned 
in a 2:1 ratio to receive nivolumab 3 mg/kg every 2 weeks 
or ICC (dacarbazine 1000 mg/m2 every 3 weeks or paclita-
xel 175 mg/m2 combined with carboplatin every 3 weeks). 
The median PFS was 4.7 months for the nivolumab group 
vs 4.2 months for the ICC group (HR 0.82). However, the 
median OS did not differ between the two treatment groups 
(16 months for patients treated with nivolumab versus 14 
months for patients treated with chemotherapy).28 Never-
theless, nivolumab demonstrated higher and more durable 
responses. Most patients developed adverse events related 
to treatment: 68% in the nivolumab group and 79% in the 
ICC group. The most frequent adverse events in the nivo-
lumab group were fatigue, pruritus and diarrhoea and in 
the ICC group were nausea, fatigue, and alopecia. Grades 
3 to 4 treatment-related adverse events occurred in 9% of 
the patients in the nivolumab group vs 31% of the patients 
in the ICC group. In the former group, the most common 
treatment-related grades 3 to 4 adverse events were increa-
sed serum lipase and alanine aminotransferase, fatigue and 
anaemia. Very few adverse events related to immunological 
causes requiring monitoring and potential intervention (im-
mune suppression or endocrine treatment) were noted in the 
nivolumab group. In another multicentric phase III clinical 
trial, Check-Mate-066,27 patients with BRAF wild-type me-
tastatic melanoma were randomly assigned in a 1:1 ratio to 
receive 3 mg/kg of nivolumab every 2 weeks, or 1000 mg/
m2 of dacarbazine every 3 weeks. Results showed that the 
1 year OS rate 72.9% in the nivolumab group compared 
with 42.1% in the dacarbazine group (HR for death, 0.42; 
99.79% confidence interval (CI), 0.25 to 0.73; p < 0.001). 
The median PFS was 5.1 months in the nivolumab group 
vs 2.2 months in the dacarbazine group (HR for death or 
progression of disease, 0.43; 95% CI, 0.34 to 0.56; p < 
0.001). The survival benefit associated with nivolumab was 
noted regardless of PDL-1 expression, that is, even in those 
patients negative for PDL-1 the survival was improved in the 
nivolumab group in comparison with the ICC group. This 
trial reinforced the safety profile of nivolumab. The inciden-
ce of treatment-related adverse events of any grade was si-
milar in the nivolumab group and the dacarbazine group 
(74.3% vs 75.6%). However, treatment-related grade 3-4 
adverse events were reported less frequently in the nivolu-
mab group (11.7% vs 17.6%) and included fatigue, pruritus 
and nausea. Immune-related adverse effects were uncom-
mon with nivolumab and included diarrhoea (10%) and ele-
vated alanine aminotransferase level (10%). Globally, this 
study demonstrated that nivolumab was associated with sig-
nificant improvements in OS and PFS, as compared with 
dacarbazine.
c) Dosage and administration of nivolumab
Nivolumab is currently approved for patients with unre-
sectable or metastatic melanoma and disease progression 
following ipilimumab and, if BRAF V600 mutation positive, a 
BRAF inhibitor. The recommended dosage is 3 mg/kg once 
every 2 weeks, administered as a 60-minutes intravenous 
infusion.29
2.2.2 – Pembrolizumab 
a) Mechanism of action:
Pembrolizumab is another highly selective humanised 
monoclonal antibody of the IgG4 isotype against PD-1. By 
binding to PD-1, pembrolizumab blocks its interaction with 
PD-L1 and PD-L2, thereby potentiating T-cell responses and 
reactivating anti-tumour  immunity.8,14,30 This drug improves 
the antigen responsiveness of immune cells in vitro (e.g., 
enhancing the production of several cytokines, including in-
terleukin (IL)-2, IL-6, IL- 17, interferon gamma (IFN-γ) and 
tumour necrosis factor-a (TNF-α), by activated T cells.31 
b) Long-term efficacy and toxicity 
Key data supported the efficacy of pembrolizumab in 
the treatment of advanced melanoma. In Keynote 001,32 a 
phase I study, pembrolizumab (formerly known as labroli-
zumab) was evaluated in patients with melanoma refractory 
to other immune therapy or BRAF inhibitors. Patients were 
treated with pembrolizumb at 10 mg/kg every 2 weeks, re-
sulting in a high rate of sustained tumour regression with a 
reasonable safety profile. 
Based on data from Keynote 001, in the phase II keyno-
te 002 study two pembrolizumab dosages (2 or 10 mg/kg 
every 3 weeks) were compared with ICC in adults with ipi-
limumab-refractory advanced melanoma.33 Results showed 
that the two pembrolizumab doses reduced the risk of di-
sease progression or death compared with ICC and were 
well tolerated compared with chemotherapy, with fewer 
treatment-related adverse events, including grade 3 to 4. 
Potentially immune-mediated adverse events with pembroli-
zumab were infrequent, mostly grade 1 or 2, and generally 
manageable with immunosuppressive therapy. The benefit 
of pembrolizumab is further strengthened by more favoura-
ble health-related quality of life scores compared with che-
motherapy. Those findings established pembrolizumab as a 
new standard of care for ipilimumab-refractory melanoma. 
Finally, Keynote 006,34 a multicentric randomised, con-
trolled, phase III study compared pembrolizumab with ipili-
mumab. In this study, 834 patients with advanced melanoma 
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were enrolled in a 1:1:1 ratio to receive pembrolizumab (10 
mg/kg of body weight) every 2 or every 3 weeks, or four 
doses of ipilimumab (3 mg/kg) every 3 weeks. The results 
showed that the 6-month PFS rates were rates were 47.3% 
for pembrolizumab every 2 weeks, 46.4% for pembrolizu-
mab every 3 weeks, and 26.5% for ipilimumab (HR for disea-
se progression = 0.58; p < 0.001 for both pembrolizumab 
dosages versus ipilimumab; 95% CI: 0.46 to 0.72 and 0.47 
to 0.72, respectively). The estimated 1-year OS rates were 
74.1%, 68.4%, and 58.2%, respectively (HR for death for 
pembrolizumab every 2 weeks, 0.63; 95% CI: 0.47 to 0.83; 
p = 0.0005; HR for pembrolizumab every 3 weeks, 0.69; 
95% CI: 0.52 to 0.90; p = 0.0036). Efficacy was similar in 
the two pembrolizumab groups. The most common treat-
ment-related adverse events of any grade in the pembroli-
zumab groups were fatigue (20.9% in the 2-week group and 
19.1% in the 3-week group), diarrhoea (16.9% and 14.4%, 
respectively), rash (14.7% and 13.4%, respectively) and pru-
ritus (14.4% and 14.1%, respectively). Grades 3 to 4 ad-
verse events occurred in less than 1% of patients, except for 
diarrhoea (2.5% and 1.1%, respectively). For ipilimumab, 
the most frequent adverse events were pruritus (25.4%), 
diarrhoea (22.7%), fatigue (15.2%) and rash (14.5%), with 
grades 3 to 5 severity in less than 1% of patients, except 
for diarrhoea (3.1%) and fatigue (1.2%). Adverse events 
of special interest on the basis of the likely autoimmune or 
immune-related mechanism observed most frequently with 
pembrolizumab were hypothyroidism (10.1% in the 2-week 
group and 8.7% in the 3-week group) and hyperthyroidism 
(6.5% and 3.2%, respectively). In the ipilimumab group, the 
most common adverse event of special interest was colitis 
(8.2%). Hypothyroidism and hyperthyroidism were more fre-
quent in the pembrolizumab groups, whereas colitis and hy-
pophysitis were more frequent in the ipilimumab group. The 
mean duration of exposure was 164 days among patients 
receiving pembrolizumab every 2 weeks, 151 days among 
those receiving pembrolizumab every 3 weeks and 50 days 
for those receiving ipilimumab. However, the rates of treat-
ment-related adverse events of grades 3 to 5 severity were 
lower in the pembrolizumab groups (13.3% and 10.1%) 
than in the ipilimumab group (19.9%). This trial demons-
trated that pembrolizumab, as compared with ipilimumab, 
significantly prolonged PFS and OS with fewer high-grade 
toxic events in patients with advanced melanoma. 
A recent multicentric phase III study35 consolidated data 
from Keynote 006, showing that pembrolizumab continued 
to provide superior OS versus ipilimumab, with no differen-
ces between pembrolizumab dosing schedule.
c) Dosage and administration of pembrolizumab 
Pembrolizumab is currently approved for patients with 
unresectable or metastatic melanoma. The recommended 
dosage is 2 mg/kg administered through a 30-minutes in-
travenous infusion every 3 weeks. Patients with the first signs 
of disease progression should continue to receive pembroli-
zumab until disease progression is confirmed.36
3 – IMMUNE CHECKPOINT INHIBITORS: COMBI-
NED IMMUNOTHERAPY  
3.1 – Principles 
Targeting different checkpoint inhibition pathways tri-
ggers a different set of immune responses, based on a study 
on ex-vivo analyses of tumour tissue samples and blood-de-
rived, purified human immune cells collected from patients 
treated with momotherapy with nivolumab, ipilimumab or 
combination therapy with nivolumab plus ipilimumab.37 Pa-
thway analysis revealed that CTLA-4 blockade induces a 
proliferative signature predominantly in a subset of transi-
tional memory T cells, while PD-1 blockade instead leads 
to changes in genes implicated in cytolysis and natural ki-
ller cell function. Upregulation of genes was substantially 
higher in patients treated with combination therapy (442 
genes upregulated) than in those treated with nivolumab 
or ipilimumab monotherapy (36 and 26 genes upregula-
ted, respectively). Therefore, a combination blockade leads 
to non-overlapping changes in gene expression, including 
proliferation-associated and chemokine genes. 
Likewise, oncolytic virus may have an attractive synergy 
interaction with immunotherapy as they directly lyse tumor 
cells, leading to the release of soluble antigens, danger sig-
nals and type I interferons, which drive anti-tumour immu-
nity, among other immunologic functions.38 Cytokines, well 
known as potent immune modulating agents, might also 
concur in this cytolysis activity.39
3.2 - Ipilimumab plus nivolumab
Some studies have shown that nivolumab and ipilimu-
mab have complementary activity in metastatic melano-
ma.40,41 These findings were confirmed in a randomised, 
double-blind, phase III study, in which nivolumab alone or 
nivolumab plus ipilimumab were compared with ipilimumab 
alone in patients with metastatic melanoma.42 In this study, 
945 previously untreated patients with unresectable stage III 
or IV melanoma were enrolled in a 1:1:1 ratio to receive ni-
volumab alone, nivolumab plus ipilimumab, or ipilimumab 
alone. The results showed that the median PFS was 11.5 
months (95% CI: 8.9 to 16.7) for combined therapy, as com-
pared with 2.9 months (95% CI: 2.8 to 3.4) for ipilimumab 
(HR for death or disease progression, 0.42; 99.5% CI: 0.31 
to 0.57; p < 0.001) and 6.9 months (95% CI: 4.3 to 9.5) for 
nivolumab (HR for the comparison with ipilimumab, 0.57; 
99.5% CI: 0.43 to 0.76; p < 0.001). The incidence of ad-
verse events was lowest in the nivolumab group and highest 
in the combination group. Grade 3-4 treatment-related ad-
verse events occurred in 16.3% of the patients in the nivo-
lumab group, 55.0% in the nivolumab+ipilimumab group 
and 27.3% in the ipilimumab group. This study demons-
trated that nivolumab alone or combined with ipilimumab 
resulted in significantly longer PFS than ipilimumab alone. 
The 3-year OS outcomes of the previous trial were repor-
ted later.43 This study showed that at a minimum follow-up 
of 36 months, the median OS had not been reached in the 
nivolumab-plus-ipilimumab group and was 37.6 months in 
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the nivolumab group, as compared with 19.9 months in the 
ipilimumab group (HR for death with nivolumab plus ipili-
mumab vs ipilimumab, 0.55 p < 0.001; HR for death with 
nivolumab vs ipilimumab, 0.65 [p < 0.001]). The OS rate at 
2 years was 64% in the nivolumab-plus-ipilimumab group 
and 59% in the nivolumab group, as compared with 45% 
in the ipilimumab group. The 3-year OS rate was 58% in 
the nivolumab-plus-ipilimumab group and 52% in the ni-
volumab group, as compared with 34% in the ipilimumab 
group. This study corroborated that among patients with 
advanced melanoma, significantly longer OS occurred with 
combination therapy with nivolumab plus ipilimumab or 
with nivolumab alone than with ipilimumab alone. 
On the basis of this data, the FDA approved combined 
use of ipilimumab and nivolumab for the treatment of stage 
IV melanoma.
3.3 - Pembrolizumab plus ipilimumab 
Pembrolizumab in combination with ipilimumab was 
evaluated in the KEYNOTE-029, a multicentric open-label, 
phase Ib trial.44 This study showed that standard-dose pem-
brolizumab (2 mg/kg) given in combination with four doses 
of low-dose ipilimumab (1 mg/kg) followed by standard-
-dose pembrolizumab has a manageable toxicity profile 
and provides robust anti-tumour activity in patients with ad-
vanced melanoma. These data suggest that standard-dose 
pembrolizumab plus reduced dose ipilimumab might be a 
tolerable and efficacious treatment option for patients with 
advanced melanoma. However, more data is needed, and a 
randomised phase II trial of alternative dosing strategies of 
this combination is underway.
3.4 - Talimogene laherparepvec (T-VEC) plus im-
mune checkpoint inhibitors
T-VEC is an oncolytic attenuated herpes simplex virus 
type 1 (HSV-1), engineered to express GM-CSF. To date is 
the only that has been approved for cancer treatment, spe-
cifically for advanced melanoma. Phase Ib clinical trial in 
19 patients with advanced melanoma, intratumoral T-VEC 
administration followed by addition of a standard intrave-
nous dose of the anti-CTLA4 antibody ipilimumab (3 mg/kg) 
showed promising results with acceptable toxicity.45 These 
results supported a subsequent Phase II randomised clini-
cal trial in 198 patients with unresectable stage IIIB–IV me-
lanoma that compared combination treatment using T-VEC 
and ipilimumab to ipilimumab alone. It found a significant 
improvement in response rate (38% with the combination vs 
18% with ipilimumab alone; OR 2.9; 95% CI 1.5–5.5; p = 
0.002), with no increase in the incidence or severity of se-
rious adverse effects with combination treatment, therefore 
showing that this combination had greater anti-tumour ac-
tivity without additional safety concerns.46 T-VEC and pem-
brolizumab combination has also been tested in a phase I 
study of 21 patients with unresectable stage IIIb/IV melano-
ma by injecting lesions and with no prior systemic therapy. 
Although the sample size was small, data showed 57.1% 
objective response, encouraging further studies.47 A larger 
randomised phase III trial is currently underway to evalua-
te this combination in comparison to pembrolizumab alone 
(MASTERKEY-265).
3.5 NKTR-214 plus nivolumab 
Cytokines, namely interleukin-2 (IL2) an endogenous 
agonist of the IL2 pathway and a well described stimula-
tor of CD8+ T cell (CD8 T) and NK cells, which had been 
approved during the 1990s by FDA the for the treatment of 
metastatic melanoma, might also concur in this cytolysis ac-
tivity. However, doses of IL2 needed to activate CD8 T cells 
and NK cells are high and associated with severe toxicity, 
which limited its use.38 NKTR-214 is a clinical-stage biolo-
gic pro-drug that comprises IL2 protein bound by multiple 
releasable polyethylene glycol (PEG) chains. In this highly 
PEG-bound form, IL2 is inactive, but it expands directly in 
the tumor microenvironment and activates specific cancer-
-fighting T cells and natural killer (NK) cells and increases 
expression of cell-surface PD-1, with minimized unwanted 
systemic toxicity of IL-2.38 Preliminary data from the ongoing 
PIVOT Phase I/II Study was presented at ASCO 2018, de-
monstrating safety and efficacy, and thus encouraging fur-
ther phase III studies.48
4 - IMMUNE CHECKPOINT INHIBITORS IN AN AD-
JUVANT SETTING
The likelihood of systemic metastatic disease among pa-
tients with stage III melanoma correlates closely with micros-
copic versus palpable nodal disease and with the number 
of positive nodes. The population of patients with stage III 
melanoma is heterogeneous, with disease-specific survival 
rates of 78% among patients with stage IIIA disease, 59% 
among those with stage IIIB disease, and 40% among those 
with stage IIIC disease.2,49 Patients with the largest metas-
tasis of more than 1 mm have a significantly higher risk of 
recurrence or death than those with the smallest metastasis 
of 1 mm or less (50). In this setting, ipilimumab was investi-
gated at a dose of 10 mg/kg (against the 3 mg/kg used in 
metastatic disease) every 3 weeks for four doses, then every 
3 months for up to 3 years or until disease recurrence or 
an unacceptable level of toxic effects occurred in patients 
who had undergone complete resection of stage III mela-
noma in a phase 3 clinical trial.51 In this study, recurrence 
free survival was the primary end point and overall survival 
(OS), distant metastasis-free survival, and safety were the 
secondary end points. At a median follow-up of 5.3 years 
the results showed significantly higher rates of recurrence-
-free survival, OS, and distant metastasis–free survival than 
placebo. The 5-year rate of recurrence-free survival was 
40.8% in the ipilimumab group, as compared with 30.3% in 
the placebo group (HR for recurrence or death = 0.76; 95% 
CI: 0.64 to 0.89; p < 0.001). The rate of OS at 5 years was 
65.4% in the ipilimumab group, as compared with 54.4% in 
the placebo group (HR for death = 0.72; 95.1% CI:  0.58 
to 0.88; p = 0.001). The rate of distant metastasis-free 
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survival at 5 years was 48.3% in the ipilimumab group, as 
compared with 38.9% in the placebo group (HR for death 
or distant metastasis = 0.76; 95.8% CI: 0.64 to 0.92; p = 
0.002). However with such a high dose of ipilimumab, ad-
verse events, mostly immune-related of grade 3 or 4 events, 
were significantly higher in the ipilimumab group (41.6% vs 
2.7%) and led to the discontinuation of treatment in appro-
ximately 40% of the patients by the end of the initial dosing 
period.
Recently, a phase III trial evaluated the efficacy of nivolu-
mab versus ipilimumab for adjuvant therapy in patients with 
resected advanced melanoma.52 Patients were randomly as-
signed (1:1) to receive an intravenous infusion of either ni-
volumab (3 mg/kg, every 2 weeks) or ipilimumab (10 mg/kg 
every 3 weeks for four doses and then every 12 weeks up to 
one year or until disease recurrence, unacceptable level of 
adverse effects or withdrawal of consent). The primary end 
point was recurrence-free survival. At a minimum follow-up 
of 18 months, the 12-month rate of recurrence-free survival 
was 70.5% (95% CI: 66.1 to 74.5) in the nivolumab group 
and 60.8% (95% CI: 56.0 to 65.2) in the ipilimumab group 
(HR for disease recurrence or death = 0.65; 97.56% CI: 
0.51 to 0.83; p < 0.001). 
Treatment related grade 3 or 4 adverse events were re-
ported in 14.4% of the patients in the nivolumab group and 
in 45.9% in the ipilimumab group, which led to treatment 
descontinuation in 9.7% and 42.6% of the patients, respec-
tively. Similar to previous study, these results may reflect the 
use of high doses of ipilimumab.
5 - IMMUNE CHECKPOINT INHIBITORS IN BRAF 
MUTATED MELANOMA
Activating mutation of the serine-threonine kinase BRAF 
gene is the most frequent genetic alteration in melanoma, 
observed in about 35%-50% of skin melanomas. The se-
cond most frequent genetic alteration activates the RAS on-
cogene and is observed in 10%-25% of the melanomas.8,9
Agents directly targeting the mutated BRAF (BRAF inhi-
bitors) such as vemurafenib and dabrafenib have also 
shown to improve the outcomes of patients with advanced 
melanoma.10,11 They classically induce earlier anti-tumour 
activity and, therefore, in most cases BRAF inhibitors are 
considered the preferred option to treat patients with rapi-
dly growing tumors carrying this BRAF mutation. However, 
acquired resistance occurs in half of the patients after ap-
proximately six months of treatment.10,11 The addition of a 
MEK inhibitor results in extension of the time to resistance, 
translating into longer median PFS of treated patients.53,54 
On the other hand, treatment of melanoma with an ICI, 
has lower response rate but the response is much more 
durable, lasting for years.55 For this reason, it was sugges-
ted that combination of BRAF/MEK inhibitor and ICI will 
significantly improve overall survival time.56,57 However, an 
early phase clinical study evaluating the combination of ve-
murafenib with ipilimumab showed high toxicity (including 
hepatotoxicity) and required discontinuation of the study.58 
Indeed, either target therapy or ICI can induce a good 
response in BRAF mutated melanoma, either as first line, or 
in previously treated patients. Nevertheless, in spite of the di-
verse treatment strategies, there is little insight into the most 
effective treatment for patients with BRAF mutant melanoma. 
Currently, phase III study results comparing the efficacy of 
targeted therapy and ICI in patients with BRAF mutation are 
still lacking, but it seems consensual that sequential therapy 
with ICI and BRAF/MEK inhibitor is beneficial, although the 
optimal sequence remains to be established.59,60
6 - BIOMARKERS UNDERLYING THE CONCEPT OF 
“CANCER IMMUNOGRAM”
Biomarkers in cancer research are defined as “A biologi-
cal molecule found in blood, other body fluids, or tissues that 
is a sign of a normal or abnormal process, or of a condition 
or disease. A biomarker may be used to see how well the 
body responds to a treatment for a disease or condition." (in 
NCI Dictionary of Cancer Terms, National Cancer Institute, 
2015). Biomarkers can be classified as diagnostic (help to 
diagnose the current condition), prognostic (help to estimate 
whether the cancer will progress or will remain stable in the 
absence of treatment) or predictive (help to predict how well 
a patient will respond to treatment).61 
Although ICI has marked efficacy in advance melanoma, 
only a subset of the patients has durable responses with im-
munotherapy.62 Thus, which patients would benefit with ICI? 
Is it possible to individualize the therapeutic schedule ac-
cording to the patient? In an attempt to collaborate in pre-
dictive biomarker research and treatment choice guidance, 
Blank CU et al proposed a framework called “cancer immu-
nogram”, which describes the different interactions between 
cancer and the immune system.63 To build this framework, 
the authors suggested the inclusion of seven classes of pa-
rameters (tumor foreignness; general immune status, im-
mune cell infiltration, absence of checkpoints, absence of 
soluble inhibitors, absence of inhibitory tumor metabolism 
and tumor sensitivity to immune effectors) that characterize 
aspects of cancer-immune interactions. For each parameter 
possible biomarkers were assigned that should be obtained 
from the combination of tumor genomics, immunohistoche-
mistry, and standard assays on the peripheral blood com-
partment (Fig. 2 A). Those parameters must be addressed 
and ideally scored in each patient. “Cancer immunogram” 
should also have value in relapsing cases as after restoring 
a parameter with a targeted therapy, a different one may be 
lost as a result of relapse (Fig. 2B). 
Despite being urgently needed, to date none of these 
predictive biomarkers has been validated for immunothera-
peutic agents in melanoma.61,62
7 - PARTICULAR SETTINGS: BRAIN METASTASIS 
AND MONITORING OF THERAPEUTIC RESPONSE
7.1 - Brain Metastasis 
Brain metastases occur in up to 60% of patients with me-
tastatic melanoma and classically confer a worse prognosis.2 
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Risk factors for melanoma brain metastasis (MBM) inclu-
de male gender, primary disease of head or neck, presen-
ce of visceral or nodal metastases, increased serum lactate 
dehydrogenase (LDH) levels and high Clark’s level/Breslow 
thickness of the primary disease.2,64 Typically MBM present ini-
tially as headache, seizures, and neurological impairment.65 
 The central nervous system (CNS) is the major site of 
treatment failure and of the disease progression even when 
extracranial disease is controlled.65 This may be due to the 
inability of drugs to target the CNS (blood-brain barrier), the 
abundance of ATP-binding cassette export pumps and also 
the unique microenvironment of the brain that shapes the 
transcriptional and phenotypic behavior of brain-resident 
melanoma cells.65-67
Until recently, therapeutic options for MBM were limi-
ted, largely consisting of surgery and radiation therapy (RT) 
in the form of stereotactic radiosurgery.66 
It has been shown that the brain inflammatory microenvi-
ronment is critical for development of MBM, namely the pre-
sence of immune cells within the CNS, which promote cross 
talk, and key signaling events between metastatic cells and 
systemic immune cells. Immune cells such as glia (including 
microglia, oligodendrocytes and astrocytes) and macropha-
ges create a suitable environment for development of brain 
metastasis by promoting growth through the production of 
various factors and chemokines. Regarding the close interac-
tion between brain metastases and immune cells, ICI starts to 
be considered as potentially targeting also MBM.65,66,68,69 ICI 
do not directly act on the tumor but they remove immuno-
logical “brakes” and allow activation of anti-tumour T cells, 
either during the priming phase (anti-CTLA4) or during the 
effector phase (anti-PD1). T cells are then able to cross the 
blood brain barrier and induce a response against MBM.14,66 
Ipilimumab was the first agent approved for MBM mainly 
based on improved outcomes in retrospective studies.66,70 
Pembrolizumab also showed activity against MBM.71 Com-
bination and sequential immunotherapy must be addressed 
as some patients with intracranial disease have respon-
ded to pembrolizumab after ipilimumab therapy whereas 
others have their disease stabilized following combination 
of pembrolizumab and ipilimumab after sequential failure 
of isolated ipilimumab and pembrolizumab.66,72 Meanwhile, 
systematic reviews also support the combination of ICI with 
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Figure 2B - (Adapted from Blank CU, et al. Science. 2016; 352:658-6063): “Cancer immunogram” is also useful in cases of non-responding 
patients, as shown in the following example:  initially a patient with melanoma scored well with respect to all parameters in the cancer immunogram, 
except for strong expression of PD-L1 at the tumour site. Based on this analysis, a single agent PD-1 blockade was the treatment of choice and the 
patient experienced a clinical response after restoring this parameter by PD-1 blockade treatment (heptagon restored). However, mechanisms of immune 
evasion, led to tumour insensitivity to T cell effector mechanisms, and consequently to relapse. According to the “cancer immunogram” the relapsing 
patient scored unfavorably concerning tumour sensitivity of immune effector, a different pre-treatment scenario, and perhaps will benefit from another 
treatment option.
Figure 2A - (Adapted from Blank CU, et al. Science. 2016; 
352:658-6063): The “cancer immunogram” proposed by Blank et al. 
All 7 parameters, and their potential biomarkers (in italic green) are 
represented in the circle. Desirable states are located in blue, thus in 
the ideal scenario the patient fits all parameters, and their link gave rise 
to a perfect heptagon. Progressive undesirable states are shown in the 
red gradient. The loss of one or more desirable states destabilizes the 
heptagon and indicates the need for a particular therapy (according to 
the parameter (s) lost) to restore the heptagon (desirable state).
PD - L1 (programmed cell death protein 1 ligand), MHC (major his-
tocompatibility complex), IFN- γ (Interferon gamma), LDH (lactate 
dehydrogenase), IL-6 (Interleukin – 6), CRP (C-reactive protein). 
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stereotactic radiosurgery or surgery.73-75 Therefore, despite 
the shy results of the previous studies, prospective clinical 
trials must be conducted to accurately assess the efficacy of 
ICI on MBM and to determine the correct sequence of local 
and systemic therapies. Currently, there are many on-going 
clinical trials on this topic.66
7.2 - Monitoring therapeutic response
It is noteworthy that the unique anti-tumour mecha-
nisms elicited by the ICI gave rise to a different response 
pattern which is no longer appropriately assessed by con-
ventional tumor response criteria such as the WHO cri-
teria76 and Response Evaluation Criteria in Solid Tumours 
(RECIST).77 Indeed, a subset of patients under ICI therapy 
develops an unconventional response pattern (“pseudo-
progression”) e.g. a response is detected only after a first 
increase in tumor burden or during/after new lesions have 
developed.78 Pseudoprogression reflects T-cell infiltration 
driven by immune activation rather than tumor progres-
sion, can be confirmed only by serial imaging, and ICI the-
rapy should not be stopped during this period.79 Events like 
this would be classified as tumor progression according 
to the WHO or RECIST criteria and not as pseudoprogres-
sion. Consequently, new criteria for disease progression, 
the immune-related response criteria (irRC) were created, 
whose key features include: confirmation of disease pro-
gression on two consecutive scans (at least 4 weeks apart) 
and inclusion of new lesions in the sum of lesion mea-
surements.78,80 Regardless of clinical and radiologic mo-
nitoring, we should be aware that ICI therapy results from 
a complex interplay between the tumor and the immune 
system, and as such individual patterns of clinical response 
are expected.80 Therefore “cancer immunogram”, mentio-
ned above, would be crucial to evaluate therapeutic res-
ponse and eventual relapses concerning ICI.63 (Fig. 2B).
8 - FUTURE PERSPECTIVES: NEWLY EMERGING 
IMMUNE CHECKPOINT INHIBITORS
There has been an increasing interest in searching addi-
tional ICI that may affect novel therapeutic targets in can-
cer. Recent advances have identified several novel immune 
checkpoint targets, including indoleamine 2,3-dioxygenase 
1 (IDO1), PD-1ligands (PD-L1 and PD-L2), lymphocyte acti-
vation gene-3 (LAG-3), B and T  protein 3 (Tim-3),  B- and 
T-lymphocyte attenuator (BLTA) and glucocorticoid-induced 
TNFR family related gene (GITR)14,81-83 (Fig. 1). 
8.1 - IDO1 inhibitors
Indoleamine 2,3-dioxygenase 1 (IDO1) is an intra-
cellular cytosolic enzyme that regulates the degradation 
of tryptophan to N-formylkynurenine. Tryptophan deple-
tion induces T-cell cycle arrest, increases their apoptosis 
by inhibiting the mechanistic target of rapamycin complex 
1 (mTORC1), and induces a stress response that activates 
the general control nondepressible-2 (GCN2). Traditionally 
the immunosuppressive effect of IDO1 has been attributed 
mainly to reducing levels of tryptophan in the tumor mi-
croenvironment.14,84,85
Pre-clinical studies are now focusing on selective IDO 
inhibitors. Epacadostat is an orally available IDO1-selective 
inhibitor under active clinical investigation, and the most ad-
vanced in development. The lack of anticancer activity as 
a monotherapy has positioned epacadostat in combination 
with approved ICIs. Concerning melanoma, epacadostat 
combined with pembrolizumab is currently under a phase III 
clinical trial (NCT02752074).84
8.2 - PDL-1 inhibitors
PD-L1 and PD-L2 are PD-1 ligands expressed in mul-
tiple tissues. PD-L1 is widely expressed in a variety of he-
matopoietic and non-hematopoietic cells, and also in many 
human cancer types. PD-L2 tumor expression is less fre-
quent than PD-L1 and is limited to antigen-presenting cells, 
macrophages, Th2 cells, and non-hematopoietic cells in the 
lung. Targeting PD-L1 instead of PD-1 offers a potential ad-
vantage in that PD-L2 remains uninhibited.86 
Atezolizumab (a fully humanized engineered IgG1 mo-
noclonal antibody against PD-L1 that contains a modified 
Fc receptor) and durvalumab (a Fc optimized monoclonal 
IgG1 directed against PD-L1) have shown encouraging re-
sults in phase I studies when combined with an anti-MEK 
or anti-BRAF in treatment of metastatic melanoma.86-88 A 
phase III study has been designed to assess cobimetinib, 
vemurafenib and atezolizumab in combination versus co-
bimetinib plus vemurafenib (with placebo) for patients with 
previously untreated BRAF mutant metastatic melanoma 
(NCT02908672).86
8.3 - Anti-LAG-3
LAG-3 is a CD4 homolog activation induced co-receptor 
of the T cell receptor that binds with high affinity to major 
histocompatibility complex (MHC) class II molecules.69,86,87 
Through its interaction with MHC class II, LAG-3 controls the 
response, activation, and growth of T-cells.89
Relatlimab is an anti-LAG-3 antibody, which is being in-
vestigated, alone and in combination with other treatments, 
in several types of cancer, including melanoma.89 A phase I/
II study (NCT01968109) is currently investigating the safety, 
tolerability, and effectiveness of relatlimab in combination 
with nivolumab in melanoma patients whose disease pro-
gressed after prior anti–PD-1 therapy. Initial encouraging 
results supported recruitment for a phase III study.91 
8.4 - Anti-TIM-3
T-cell immunoglobulin mucin-3 (TIM-3) belongs to TIM 
proteins group, which are implicated in the regulation of 
innate and adaptive immune responses. Particularly, TIM-3 
was originally identified as a negative immune regulator 
which is expressed on T helper 1 (Th1) cells. The interaction 
with its ligand galectin-9 inhibits Th1 responses and indu-
ces peripheral tolerance.14,92,93 Further investigation indica-
ted that TIM-3 is also expressed on multiple cells types.93 
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Concerning cancer, recent studies demonstrated that TIM-3 
is highly expressed within the tumor microenvironment due 
to tumor associated antigens stimulation and suggest that 
this protein could play a direct role in the functional matu-
ration of tumor-infiltrating Tregs and also in their immuno-
suppressive function within the tumor microenvironment.87,93
Pre-clinical studies found that coexpression of Tim-3 and 
PD-1 in CD8 T cells represent the most exhausted population 
of tumor-infiltrating Tregs and thus simultaneous blockade 
of Tim-3 and PD-1 could restore the anti-tumour activity of 
these exhausted T cells.93,94 Indeed, later Koyama S et al95 
reported that the adaptive resistance to  PD-1/PD-L1 ICI in 
lung cancer are due to upregulation of alternative immune 
checkpoints, notably TIM-3. Using a mouse model, they de-
monstrated that the addition of TIM-3 antibody overcomes 
resistance to PD-1 blockade. This study highlights the poten-
tial of using combinations of ICIs for enhancing the thera-
peutic success rates.
Currently, the humanized anti-TIM-3 antibody TSR-022 is 
under clinical trial, to be evaluated in monotherapy and in 
combination with an anti-PD-1 antibody in patients with ad-
vanced solid tumors and limited available treatment options 
(NCT02817633). 
Pre-clinical studies have been shown that upon its admi-
nistration, TSR-022 binds TIM-3 and activates antigen-spe-
cific T lymphocytes and cytotoxic T-cell mediated tumor lysis 
reducing tumour growth.81 
8.5 - Anti-BLTA
BTLA is an immunoglobulin domain containing glycopro-
tein expressed on T cells, resting B cells, macrophages, den-
dritic cells and natural Killer cells that have been described 
as an inhibitory receptor on T cells with structural and func-
tional similarities to CTLA-4 and PD-1.14,82,96 
Unexpectedly herpesvirus entry mediator (HVEM), a 
tumor necrosis factor receptor, was identified as a natural 
ligand for BTLA in both mice and humans.97 
In melanoma patients, tumor antigen–specific effector 
CD8+T cells persistently expressed high levels of BTLA and 
remained susceptible to functional inhibition by its ligand 
HVEM, which was also found to be highly expressed by me-
lanomas.97 L Derre et al98 found that the addition of CpG 
oligodeoxynucleotides to the vaccine with Melan-AMART-1 
formulation resulted in enhanced CD8+ T cell responses, 
due to downregulation of BTLA and resistance to BTLA-
-HVEM–mediated inhibition. Thus BTLA blockade by targe-
ting BTLA and HVEM may provide an additional therapeutic 
option for melanoma, but it needs to be further elucidated.82 
8.6 - GITR agonists
GITR is a costimulatory TNF receptor super family mem-
ber, which expands CD8+ T effector memory cell population 
while promoting the loss or inhibition of Tregs.83 BMS-
986156 is a fully human IgG1 agonist monoclonal antibo-
dy that binds GITR and promotes effector T-cell activation 
and possible reduction/inactivation of regulatory Tcells. In 
this setting, a phase I/IIa study of BMS-986156 alone and 
in combination with nivolumab in patients with advanced 
solid tumors (NCT02598960) is ongoing. Preliminary data 
demonstrated a good safety profile in both groups, but anti-
-tumour activity was only observed with BMS-986156 plus 
nivolumab at doses predicted to be biologically active. Fur-
ther evaluation of this combination in patients with advanced 
solid tumors is underway.99
9 - CONCLUSION
Immunotherapy with checkpoint inhibitors revolutionised 
the treatment of the patients with unresectable stage III or 
stage IV melanoma wild-type for BRAF.100 The percentage 
of patients with poor prognostic markers, such as elevated 
serum LDH, impaired overall performance, has differed sig-
nificantly between the trials, which may have influenced the 
patients’ survival outcomes. Of note, as previously mentio-
ned, those patients with MBM, given their worse progno-
sis, were not considered in most of the studies. However, 
globally, the studies demonstrated robust data on efficacy 
of anti-CTLA-4 and anti-PD1 on advanced melanoma, re-
garding the durability of their responses and potential for 
long-term survival, despite the concerning autoimmune side 
effects. Considering the distinct immune regulating roles of 
PD-1 and CTL-4, differences in outcomes and drug safety 
profile are expected. CTLA-4 primarily regulates effector T 
cell responses within the peripheral tissues.101 On the other 
hand, PD-1 is a related inhibitory T cell receptor, in which 
its ligands, namely PD-L1, are expressed locally within the 
tumour microenvironment by stromal, immune cells, and by 
the tumour itself. Thus, targeting this pathway may have a 
more selective anti-tumour response and potentially fewer 
adverse effects.102 A recent meta-analysis from the main 
trials representative of the new treatment options in advan-
ced metastatic melanoma confirmed that anti-PD-1 agents 
have higher response rates103 (Table 1).
As immune checkpoints play a crucial role in maintaining 
tolerance to self-antigens, treatment with their inhibitors is 
associated with organ-specific autoimmune phenomenon. 
The majority (> 70%) of patients treated with ipilimumab 
developed some form of immune-related adverse events 
with a quarter of cases considered severe.104 The majority 
of events involve the skin (rash, pruritus, vitiligo), gastroin-
testinal tract (diarrhoea, colitis), endocrine system (thyroid 
disorders, hypophysitis) and the liver (elevated liver enzy-
mes, hepatitis), and are dose-related. PD-1 inhibitors are 
much better tolerated than ipilimumab. Fatigue is a com-
mon problem, and immune-related adverse events occur 
less frequently and with lesser severity, but involved organs 
are similar.105 
Further, regarding the distinct immune response when 
targeting PDL-1 or CTLA-4, the combined checkpoint blo-
ckade results in higher and more sustained responses; howe-
ver, toxicity is substantially higher. In this setting combined 
synergistic therapy seems to be the next step in the treat-
ment of advanced melanoma according to the recent results 
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concerning the newly emerging immune checkpoints.14,81-83 
In BRAF mutated melanoma the sequential therapy with ICI 
and target therapy seems to extend the therapeutic respon-
se, although the optimal sequential schedule remains to be 
elucidated.59,60 
It is well demonstrated that immunotherapy with ICI 
have yielded promising results in advanced melanoma. 
PD-1 inhibitors are now the standard of care in melanoma 
due to their better safety profile and prolonged OS and 
PFS. Currently, in Portuguese Institute of Oncology, Lisbon, 
immunotherapy with pembrolizumab is the therapeutic of 
choice for patients with BRAF wild-type advanced melano-
ma. Despite the remarkable success of these new immu-
notherapies in melanoma patients, the efficacy of these 
agents varies among patients with similar tumor charac-
teristics and similar burden and, at this moment, we have 
no clear identification of which patients will have a clinical 
benefit and a complete response after therapy. Similarly, 
after obtaining a complete response, there are no rules 
for maintenance therapy or for stopping and waiting to 
see. All patients under nivolumab and pembrolizumab who 
obtain clinical benefit maintain the treatment until disease 
progression or unacceptable toxicity. Some authors advo-
cate the possibility of stopping at 24 months or earlier if a 
complete response is attained, since over 90% of patients 
who attain complete response continue to respond even 
after stopping therapy and have the ability of responding 
again on re-challenging. Indeed, due to melanoma he-
terogeneity, potential adverse side effects and high costs 
of immunotherapy, suitable predictive biomarkers to as-
sess patient risk-benefit management with ICI are urgently 
needed, and should encompass the cell mediated immune 
system and the tumor infiltrating immune cells as well as 
the serum circulating factors.
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Educação Médica Contínua
1.  Which of the following is true of cutaneous 
melanoma: 
a) Cutaneous melanoma represents a minority of all 
skin cancers although it is responsible for 50 per-
cent of skin cancer deaths.
b)  The risk of metastasis correlates directly with pri-
mary tumour thickness, but not with ulceration.
c)  The incidence of melanoma is increasing however 
this trend should stabilize throughout the next two 
decades.
d)  Thirty-five to 50% of patients with cutaneous mela-
noma harbour a BRAF 600 mutation.
e) Conventional chemotherapy, has been largely 
effective in patients with unresectable or metasta-
tic melanoma, but immunotherapy using immune 
system checkpoint inhibitors are now recommen-
ded for BRAF wild-type melanoma patients in ad-
vance stages.
2. Which of the following is the wrong sentence 
about immune checkpoint inhibitors (ICI):
a) Ipilimumab is a fully human monoclonal immuno-
globulin G1 antibody against  cytotoxic T lympho-
cyte antigen – 4 (CTLA-4). 
b) Nivolumab, is a fully human monoclonal immu-
noglobulin G4 antibody against programmed 
death – 1 (PD-1).
c) Pembrolizumab is a fully human monoclonal im-
munoglobulin G4 antibody against programmed 
death – 1 (PD-1).
d) Nivolumab was the first drug introduced as immu-
notherapy for melanoma.
e) Pembrolizumab has been better tolerated than ipi-
limumab.
3. All of the following are possible adverse 
effects of immune checkpoint inhibitors (ICI), 
except:
a) Vitiligo
b) Non melanoma skin cancer 
c) Colitis 
d) Hypophysitis
e) Fatigue
4. Please point out the false sentence:
a) Targeting different checkpoint inhibition pathways 
triggers a different set of immune responses, thus 
combined therapy with anti-CTL-4 and anti-PD-1 
may result in better outcomes.
b) Based on data from phase 3 studies, the FDA ap-
proved combined use of ipilimumab and nivolu-
mab for the treatment of stage IV melanoma.
c) The population of patients with stage III melano-
ma is homogenous and they also benefit from 
adjuvant treatment with immune checkpoint inhi-
bitors.
d) The use of higher doses of ipilimumab as adjuvant 
therapy for stage III melanoma resulted in high 
percentage (40-45%) of treatment related grade 
3 or 4 adverse events.
e) As immune checkpoints play a crucial role in 
maintaining tolerance to self-antigens, treatment 
with their inhibitors is associated with organ-spe-
cific autoimmune phenomenon.
5. Which of the following is true regarding the 
therapy of advance melanoma
a) Immune checkpoints inhibitors have no activity in 
BRAF mutated melanomas.
b)  BRAF inhibitors are linked with acquired resistan-
ce, occurring in half of the patients after approxi-
mately six months of treatment.
c)  Prognostic biomarkers are urgently needed to as-
sess the risk-benefit management with immune 
checkpoints inhibitors in patients with advanced 
melanoma. 
d)  CTLA-4 primarily regulates effector T cell respon-
ses within the tumour microenvironment and PD-1 
is an inhibitory T cell receptor within the periphe-
ral tissues.
e)  To date only CTLA-4 and PD-1 have been identi-
fied as immune checkpoint targets. 
6. Currently, in Portuguese Institute of Oncology, 
Lisbon, what is the therapy of choice for pa-
tients with BRAF wild-type advanced melano-
ma? 
a) Nivolumab
b)  Ipilimumab
c)  Pembrolizumab
c)  Nivolumab + Ipilimumab
d)  Pembrolizumab + Ipilimumab
VErifiquE o quE aprENdEu
Chave: 1. d); 2. d); 3. b); 4. c); 5. b); 6. c)
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